Form D · Pharmaceuticals
Hepanova, Inc.
Gaithersburg, MD · CIK 0001792163
Offering snapshot reported Jan 8, 2021 · SEC filing
- Reported sold
- $450K Offering amount: $450K
- Investors reported
- 1 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Jan 1, 2021 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Jan 8, 2021 | Initial | $450,000 | No comparison | 1 | SEC filing |
| Oct 29, 2019 | Initial | $1,000,000 | No comparison | 1 | SEC filing |
Offering details
- Securities
- Equity
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-385713
Source: Form D, filed Jan 8, 2021. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Qisheng Li | Director, Executive |
| Ke Li | Director |
| Frank Q. Li | Director, Executive |
| Yuanzhang Wang | Director |
| Belle X Wang | Director, Executive |
Issuer details
Industry: Pharmaceuticals (See others in industry)
Address:
401 Professional Drive, Suite 108
Gaithersburg, MD, 20879
Gaithersburg, MD, 20879